Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with certain genetic ...

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...

Merck is speeding up plans to launch a new version of its top-selling cancer drug Keytruda, with less than three years to go before the patents protecting the original version expire. Keytruda ...

Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...

(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non ...

plus Keytruda (pembrolizumab) in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). Also Read: Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID ...

Keytruda market Insights: Continued dominance as a leading immunotherapy drug for multiple cancers, with expanding indications. US, NY, UNITED STATES, January 20, 2025 /EINPresswire / -- Market ...

Enfortumab vedotin plus pembrolizumab cut the risk of death by 49% vs. chemo, with a median OS of 33.8 months vs. 15.9 months. The combination therapy reduced disease progression or death risk by ...